Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.

被引：0
|
作者：
Engel-Nitz, Nicole M.
Becker, Laura
Gerdes, Randall
Hao, Yanni
机构：
[1] Optum, Eden Prairie, MN USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11504
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
    Venetis, Konstantinos
    Pepe, Francesco
    Pescia, Carlo
    Cursano, Giulia
    Criscitiello, Carmen
    Frascarelli, Chiara
    Mane, Eltjona
    Russo, Gianluca
    Salimbeni, Beatrice Taurelli
    Troncone, Giancarlo
    Rocco, Elena Guerini
    Curigliano, Giuseppe
    Fusco, Nicola
    Malapelle, Umberto
    CANCER TREATMENT REVIEWS, 2023, 121
  • [32] Physician experiences and preferences in the treatment of HR+/HER2-metastatic breast cancer in the United States: aphysician survey
    Lin, Peggy L.
    Hao, Yanni
    Xie, Jipan
    Li, Nanxin
    Zhong, Yichen
    Zhou, Zhou
    Signorovitch, James E.
    Wu, Eric Q.
    CANCER MEDICINE, 2016, 5 (02): : 209 - 220
  • [33] Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2-metastatic breast cancer
    Goyal, Ravi K.
    Carter, Gebra Cuyun
    Nagar, Saurabh P.
    Smyth, Emily N.
    Price, Gregory L.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (10) : 1699 - 1710
  • [34] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [35] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [36] Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2-metastatic breast cancer receiving palbociclib
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    CANCER RESEARCH, 2018, 78 (04)
  • [37] TREATMENT PATTERNS OF ENDOCRINE THERAPY AND CHEMOTHERAPY AMONG POST-MENOPAUSAL WO MEN WITH HR+/HER2-METASTATIC BREAST CANCER
    Lin, P. L.
    Hao, Y.
    Signorovitch, J. E.
    Kelley, C.
    Macalalad, A. R.
    Ohashi, E.
    Zhou, Z.
    Wu, E. Q.
    VALUE IN HEALTH, 2015, 18 (03) : A1221 - A1221
  • [38] COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY
    Altundag, K.
    Basaran, G.
    Oksuzoglu, B.
    Oven, B.
    Ozguroglu, M.
    Aydin, D.
    Hacibedel, B.
    Helvacioglu, K.
    Tuna, E.
    Tatar, M.
    VALUE IN HEALTH, 2016, 19 (03) : A146 - A146
  • [39] Treatment patterns and sequences among pre-menopausal women with HR+/HER2-metastatic breast cancer: A chart review study
    Dalal, A. A.
    Goldschmidt, D.
    Romdhani, H.
    Kelkar, S.
    Guerin, A.
    Wang, H.
    Caria, N.
    Sawhney, A.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [40] VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/HER2-METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY
    Richardson, D.
    Zhan, L.
    Reynolds, M.
    Odom, D.
    McRoy, L.
    Mitra, D.
    Zelnak, A.
    Jones, C.
    VALUE IN HEALTH, 2019, 22 : S527 - S527
12345